SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 198 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24 | -53.8% | 40,716 | +1.5% | 0.00% | – |
| Q2 2023 | $52 | -26.8% | 40,100 | -0.7% | 0.00% | – |
| Q1 2023 | $71 | -71.9% | 40,374 | -49.8% | 0.00% | – |
| Q4 2022 | $253 | -99.9% | 80,497 | +0.1% | 0.00% | -100.0% |
| Q3 2022 | $394,000 | +18.7% | 80,450 | +0.2% | 0.00% | – |
| Q2 2022 | $332,000 | -32.5% | 80,252 | -5.3% | 0.00% | -100.0% |
| Q1 2022 | $492,000 | -22.5% | 84,743 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $635,000 | -38.4% | 84,681 | -26.0% | 0.00% | 0.0% |
| Q3 2021 | $1,031,000 | -24.3% | 114,459 | +0.6% | 0.00% | 0.0% |
| Q2 2021 | $1,362,000 | -13.5% | 113,821 | -9.4% | 0.00% | -50.0% |
| Q1 2021 | $1,575,000 | -19.7% | 125,671 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,961,000 | +86.4% | 125,671 | +12.9% | 0.00% | +100.0% |
| Q3 2020 | $1,052,000 | +5.5% | 111,321 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $997,000 | +55.3% | 111,321 | +10.4% | 0.00% | 0.0% |
| Q1 2020 | $642,000 | -23.8% | 100,821 | +0.1% | 0.00% | 0.0% |
| Q4 2019 | $843,000 | -25.5% | 100,721 | -19.5% | 0.00% | 0.0% |
| Q3 2019 | $1,132,000 | -15.2% | 125,121 | +1.0% | 0.00% | -50.0% |
| Q2 2019 | $1,335,000 | +31.7% | 123,921 | +16.6% | 0.00% | +100.0% |
| Q1 2019 | $1,014,000 | -17.3% | 106,321 | -0.4% | 0.00% | -50.0% |
| Q4 2018 | $1,226,000 | -40.2% | 106,771 | -11.7% | 0.00% | 0.0% |
| Q3 2018 | $2,050,000 | +19.9% | 120,921 | +0.4% | 0.00% | 0.0% |
| Q2 2018 | $1,710,000 | -9.9% | 120,421 | +20.5% | 0.00% | 0.0% |
| Q1 2018 | $1,898,000 | +16.8% | 99,921 | +0.9% | 0.00% | 0.0% |
| Q4 2017 | $1,625,000 | -4.3% | 99,071 | -12.5% | 0.00% | 0.0% |
| Q3 2017 | $1,698,000 | +153.1% | 113,230 | +48.6% | 0.00% | +100.0% |
| Q2 2017 | $671,000 | +103.3% | 76,200 | +20.0% | 0.00% | – |
| Q1 2017 | $330,000 | +20.4% | 63,501 | -29.3% | 0.00% | – |
| Q4 2016 | $274,000 | -34.1% | 89,850 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $416,000 | -20.0% | 89,850 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $520,000 | +35.4% | 89,850 | +41.5% | 0.00% | 0.0% |
| Q1 2016 | $384,000 | -33.8% | 63,500 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $580,000 | +62.0% | 63,500 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $358,000 | -55.6% | 63,500 | -12.7% | 0.00% | 0.0% |
| Q2 2015 | $807,000 | – | 72,751 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |